It is currently Sun Dec 04, 2016 4:39 pm

News News of Gilenya

Site map of Gilenya » Forum : Gilenya

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Generic Gilenya rival launched in Russia

Russian firm BioIntegrator says it has successfully launched Neskler -- the first generic version of Gilenya...Read more - http://www.ms-uk.org/MSnews
Read more : Generic Gilenya rival launched in Russia | Views : 921 | Replies : 1


Gilenya ‘prevents activation of key immune cells’

In a recent study entitled Myeloid Cells As Target Of Gilenya Action In Multiple Sclerosis, a team of scientists investigated the impact of MS treatment Gilenya on the reactivity of myeloid cells, a key group that comprises several immune cells that are activated in MS patients and the underlying cause of the condition. The study was published in the journal Neurology...Read more - http://www.ms-uk.org/MSnews
Read more : Gilenya ‘prevents activation of key immune cells’ | Views : 1131 | Replies : 0


No conclusions over best drug for Multiple Sclerosis

Two studies - one from France, the other from Denmark - came to conflicting conclusions about whether Tysabri or Gilenya offers better efficacy, researchers have reported here... Read More - http://www.ms-uk.org/MSnews
Read more : No conclusions over best drug for Multiple Sclerosis | Views : 1226 | Replies : 0


Long-term efficacy of Gilenya reinforced by new analysis

Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya. The analysis evaluated the proportion of Gilenya patients with relapsing-remitting multiple sclerosis (RRMS) achieving 'no evidence of disease activity' (NEDA-4) every year over seven years... Read More - http://www.ms-uk.org/MSnews
Read more : Long-term efficacy of Gilenya reinforced by new analysis | Views : 1018 | Replies : 0


Gilenya found to be effective ‘for up to three years’

An encouraging new analysis reveals Gilenya is an effective MS therapy for a treatment period of up to three years. The results were presented at the Annual Meeting of the Consortium of MS Centres in America... Read More - http://www.ms-uk.org/gilenya
Read more : Gilenya found to be effective ‘for up to three years’ | Views : 1317 | Replies : 0


Third case of PML reported to Novartis

Novartis has been notified of a third case of progressive multifocal leukoencephalopathy (PML) in a patient with relapsing multiple sclerosis (MS) treated with Gilenya... Read More - http://www.ms-uk.org/gilenya
Read more : Third case of PML reported to Novartis | Views : 1478 | Replies : 0


FDA issues PML warning for MS patients taking Gilenya

Following reports of progressive multifocal leukoencephalopathy among patients taking Gilenya for multiple sclerosis, the FDA has issued a warning of possible infection for those prescribed the immunosuppressant drug.... Read More - http://www.ms-uk.org/gilenya
Read more : FDA issues PML warning for MS patients taking Gilenya | Views : 1372 | Replies : 0


Study finds lesions may compromise heart rate in Gilenya....

Study finds lesions may compromise heart rate in Gilenya patients

In a recent study published in the Journal PLOS One, a team of researchers found that the autonomic cardiovascular dysfunction in MS patients with delayed heart rate re-acceleration upon Gilenya-initiation suggest MS-related central autonomic lesions may compromise heart rate re-acceleration..... Read More - http://www.ms-uk.org/gilenya
Read more : Study finds lesions may compromise heart rate in Gilenya.... | Views : 1267 | Replies : 0


Gilenya ‘found to have long-term positive effects’

A new study published in the Journal of Neurology, Neurosurgery and Psychiatry has found long-term Gilenya therapy can maintain a low disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). The study, Long-Term (up to 4.5 years) Treatment With Fingolimod (Gilenya) In Multiple Sclerosis: Results From The Extension Of The Randomised TRANSFORMS Study, was conducted by an international team of researchers..... Read More - http://www.ms-uk.org/gilenya
Read more : Gilenya ‘found to have long-term positive effects’ | Views : 1569 | Replies : 0


Researchers suggest short transition period....

Researchers suggest short transition period between RRMS therapies

A team led by researchers at the University Hospital Basel in Switzerland say they have found a short period of eight to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched from Tysabri (natalizumab) to Gilenya (fingolimod) therapy.... Read More - http://www.ms-uk.org/gilenya
Read more : Researchers suggest short transition period.... | Views : 1336 | Replies : 0


 

Login  •  Register


Statistics

Total posts 235109 • Total topics 25366 • Total members 16576


Contact us | Terms of Service